PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022 - WECT TV6-WECT.com:News, weather & sports Wilmington, NC

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker



 

NEW YORK, Feb. 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029811/PharmaPoint-Chronic-Heart-Failure---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

Summary

The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs. However, the market entry of entry of Novartis' LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug's efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.

Highlights

Key Questions Answered

- Although the CHF market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the CHF market?
- The late-stage CHF developmental pipeline is sparsely populated, however, the early stage pipeline is more active and consists of novel pharmacological as well as non-pharmacological therapeutic approaches. Will the late-stage drugs make a significant impact on the CHF market? What are the earlier-stage novel, approaches that drug developers are pursuing?
- Although the incidence of CHF in the US has been relatively constant during the last decade, its prevalence has been gradually increasing. How will epidemiological changes impact the growth of the future market?

Key Findings

- An increasing number of generic competitors present a significant barrier to growth in a market already heavily laden with generic drugs.
- The launch of Novartis's LCZ-696, a new market entrant, will drive the overall growth of the CHF market in the 7MM during 2012-2022.
- To date, no drug has demonstrated sufficient efficacy in the HF-PEF segment of the CHF population in large-scale clinical trials. This unmet need presents a large opportunity for investment by drug developers.

Scope

- Overview of CHF, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized CHF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2011-2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CHF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, including both pharmacological and non-pharmacological therapeutic approaches.
- Analysis of the current and future market competition in the global CHF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global CHF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CHF therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CHF therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 23
3.2 Prognosis 27
3.3 Quality of Life 27
3.4 Symptoms 28
4 Epidemiology 30
4.1 Risk Factors and Comorbidities 30
4.1.1 Age and sex are highly associated with the risk of chronic heart failure 32
4.1.2 History of cardiovascular disease increases the risk of developing chronic heart failure 32
4.1.3 Unhealthy lifestyles increase the risk of chronic heart failure 33
4.1.4 People with diabetes mellitus are twice as likely to develop chronic heart failure 33
4.1.5 Nearly 20% of patients with chronic kidney disease develop chronic heart failure 34
4.1.6 Comorbidities 34
4.1.7 Prognosis for chronic heart failure remains poor 35
4.2 Global Trends 36
4.2.1 United States 36
4.2.2 France 37
4.2.3 Germany 38
4.2.4 Italy 38
4.2.5 Spain 38
4.2.6 United Kingdom 39
4.2.7 Japan 39
4.2.8 China 40
4.3 Forecast Methodology 40
4.3.1 Sources Used 40
4.3.2 Forecast Assumptions and Methods 45
4.3.3 Forecast Assumptions and Methods for New York Heart Association Class Distributions 48
4.3.4 Sources Not Used 49
4.4 Epidemiology Forecast (2012-2022) 49
4.4.1 Prevalent Cases of Chronic Heart Failure 49
4.4.2 Age-Specific Prevalent Cases 52
4.4.3 Sex-Specific Prevalent Cases 54
4.4.4 Age-Standardized Prevalence 59
4.4.5 New York Heart Association Class Distributions 61
4.5 Discussion 62
4.5.1 Limitations of Analysis 64
4.5.2 Strengths of Analysis 64
5 Disease Management 65
5.1 Treatment Overview 66
5.1.1 Pharmacological Treatments 68
5.1.2 Mechanical Devices 74
5.2 US 75
5.2.1 Diagnosis and Referral Patterns 75
5.2.2 Clinical Practice 76
5.3 France 77
5.3.1 Diagnosis and Referral Patterns 77
5.3.2 Clinical Practice 78
5.4 Germany 80
5.4.1 Diagnosis and Referral Patterns 80
5.4.2 Clinical Practice 80
5.5 Italy 82
5.5.1 Diagnosis and Referral Patterns 82
5.5.2 Clinical Practice 82
5.6 Spain 84
5.6.1 Diagnosis and Referral Patterns 84
5.6.2 Clinical Practice 85
5.7 UK 87
5.7.1 Diagnosis and Referral Patterns 87
5.7.2 Clinical Practice 88
5.8 Japan 90
5.8.1 Diagnosis and Referral Patterns 90
5.8.2 Clinical Practice 90
6 Competitive Assessment 92
6.1 Overview 92
6.2 Strategic Competitor Assessment 92
6.3 Drug Profiles 95
6.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 95
6.3.2 Diuretics 98
6.3.3 Angiotensin Receptor Blockers 100
6.3.4 Beta Blockers 113
6.3.5 Procoralan (ivabradine) 125
6.3.6 Mineralocorticoid Receptor Antagonists 129
6.3.7 Digoxin 132
7 Opportunity and Unmet Need 135
7.1 Overview 135
7.2 Lack of Therapies for HF-PEF Patients 136
7.3 Lack of Therapies for Patients with Renal Impairment 137
7.4 Diagnosis of Asymptomatic Left Ventricular Dysfunction 137
7.5 Treatment of Patients with Multiple Comorbidities 138
7.6 Increase in Survival of CHF Patients 138
7.7 Unmet Needs Gap Analysis 139
7.8 Opportunity: Treatment of Patients with HF-PEF 140
7.9 Opportunity: Therapies for Patients with Renal Impairment and Multiple Comorbidities 140
7.10 Opportunity: New Drugs that Show Increase in Survival of CHF Patients 140
8 Pipeline Assessment 141
8.1 Overview 141
8.1.1 Clinical Trials by Country 142
8.2 Clinical Trials by Phase and Trial Status 143
8.3 Promising Drugs in Clinical Development 144
8.3.1 LCZ-696 145
8.3.2 Tekturna (aliskiren) 151
8.3.3 Neucardin (rhNRG-1) 155
8.4 Innovative Early-Stage Approaches 159
8.4.1 BAY 94-8862 159
8.4.2 Omecamtiv mecarbil 162
8.5 Promising Non-Pharmacological Approaches 165
8.5.1 MyoCell 166
8.5.2 C-Cure (C3BS-CQR-1) 171
8.5.3 Mydicar (rAAV1-SERCA2a) 174
9 Current and Future Players 179
9.1 Overview 179
9.2 Trends in Corporate Strategy 180
9.3 Company Profiles 181
9.3.1 Novartis 181
10 Market Outlook 185
10.1 Global Markets 185
10.1.1 Forecast 185
10.1.2 Drivers and Barriers - Global Issues 188
10.2 United States 191
10.2.1 Forecast 191
10.2.2 Key Events 195
10.2.3 Drivers and Barriers 195
10.3 France 197
10.3.1 Forecast 197
10.3.2 Key Events 200
10.3.3 Drivers and Barriers 200
10.4 Germany 201
10.4.1 Forecast 201
10.4.2 Key Events 204
10.4.3 Drivers and Barriers 204
10.5 Italy 205
10.5.1 Forecast 205
10.5.2 Key Events 207
10.5.3 Drivers and Barriers 208
10.6 Spain 209
10.6.1 Forecast 209
10.6.2 Key Events 211
10.6.3 Drivers and Barriers 212
10.7 United Kingdom 213
10.7.1 Forecast 213
10.7.2 Key Events 216
10.7.3 Drivers and Barriers 216
10.8 Japan 217
10.8.1 Forecast 217
10.8.2 Key Events 220
10.8.3 Drivers and Barriers 220
11 Appendix 223
11.1 Bibliography 223
11.2 Abbreviations 240
11.3 Methodology 244
11.4 Forecasting Methodology 244
11.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 244
11.4.2 Diagnosed CHF Population 245
11.4.3 Drug-Treated CHF Population 246
11.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 246
11.4.5 Treatment of HF-REF versus HF-PEF 246
11.4.6 Drugs Included in Each Therapeutic Class 247
11.4.7 Launch and Patent Expiry Dates 247
11.4.8 General Pricing Assumptions 248
11.4.9 Drugs Assumptions 249
11.4.10 Generic Erosion 254
11.4.11 Pricing of Pipeline Agents 254
11.5 Physicians and Specialists Included in this Study 255
11.6 Survey of Prescribing Physicians 256
11.7 About the Authors 257
11.7.1 Author 257
11.7.2 Epidemiologist 257
11.7.3 Global Head of Healthcare 258
11.8 About GlobalData 259

List of Tables

Table 1: Leading Causes of CHF 22
Table 2: Other Causes of CHF 22
Table 3: Compensatory Mechanisms in CHF 23
Table 4: Typical Symptoms of CHF 28
Table 5: NYHA Classification of HF Based on Symptoms and Physical Ability of Patients 29
Table 6: Risk Factors and Comorbidities for CHF 31
Table 7: Sources of Epidemiological Data Used for the Forecast 41
Table 8: NYHA Class Distributions 48
Table 9: All Markets, Prevalent Cases (N) of CHF, Ages ?45 Years, Men and Women, 2012-2022 50
Table 10: All Markets, Prevalent Cases of CHF, by Age, Men and Women, N (Row %), 2012 53
Table 11: All Markets, Prevalent Cases of CHF, by Sex, Ages ? 45 Years, N (Row %), 2012 55
Table 12: All Markets, Prevalent Cases of CHF by NYHA Class, Ages ?45 Years, Men and Women, N (Row %), 2012 61
Table 13: ACC/AHA Classification of HF Based on Disease Progression 65
Table 14: NYHA Classification of HF Based on Symptoms and Physical Activity of Patients 65
Table 15: Commonly Used Treatment Guidelines for CHF 67
Table 16: Most Prescribed Drugs for CHF by NYHA Class in the Major Markets, 2012 69
Table 17: Select Products Used for CHF Treatment, 2012 94
Table 18: Global Sales Forecasts ($m) for ACE inhibitors, 2012-2022 97
Table 19: Global Sales Forecasts ($m) for Diuretics, 2012-2022 100
Table 20: Global Sales Forecasts ($m) for ARBs, 2012-2022 103
Table 21: Product Profile - Diovan 105
Table 22: Diovan SWOT Analysis, 2012 107
Table 23: Global Sales Forecasts ($m) for Diovan, 2012-2022 108
Table 24: Product Profile - Atacand 110
Table 25: Atacand SWOT Analysis, 2012 111
Table 26: Global Sales Forecasts ($m) for Atacand, 2012-2022 112
Table 27: Global Sales Forecasts ($m) for Beta Blockers, 2012-2022 116
Table 28: Product Profile - Carvedilol 117
Table 29: Carvedilol SWOT Analysis, 2012 119
Table 30: Global Sales Forecasts ($m) for Carvedilol, 2012-2022 120
Table 31: Product Profile - Nebivilol 122
Table 32: Nebivilol SWOT Analysis, 2012 123
Table 33: Global Sales Forecasts ($m) for Nebilet, 2012-2022 124
Table 34: Product Profile - Procoralan 126
Table 35: Procoralan SWOT Analysis, 2012 127
Table 36: Global Sales Forecasts ($m) for Procoralan, 2012-2022 128
Table 37: Global Sales Forecasts ($m) for MRAs, 2012-2022 131
Table 38: Global Sales Forecasts ($m) for Digoxin, 2012-2022 134
Table 39: Overall Unmet Needs - Current Level of Attainment 135
Table 40: Clinical Unmet Needs - Gap Analysis, 2013 139
Table 41: CHF - Clinical Trials by Phase and Status, 2012 143
Table 42: CHF - Promising Late-Stage Pipeline, 2012 144
Table 43: Comparison of Therapeutic Classes in Development for CHF, 2012 144
Table 44: Product Profile - LCZ-696 146
Table 45: LCZ-696 SWOT Analysis, 2012 149
Table 46: Global Sales Forecasts ($) for LCZ-696, 2012-2022 150
Table 47: Product Profile - Tekturna 153
Table 48: Tekturna SWOT Analysis, 2012 155
Table 49: Product Profile - Neucardin 156
Table 50: CHF - Innovative Early-Stage Approaches, 2012 159
Table 51: Product Profile - BAY 94-8862 161
Table 52: Product Profile - Omecamtiv mecarbil 164
Table 53: CHF - Promising Non-Pharmacological Approaches, 2012 165
Table 54: Product Profile - MyoCell 168
Table 55: Product Profile - C-Cure 172
Table 56: Product Profile - Mydicar 175
Table 57: Key Companies in the CHF Market, 2012 180
Table 58: Novartis' CHF Portfolio Assessment, 2012 183
Table 59: Novartis SWOT Analysis, 2012 184
Table 60: Global Sales Forecasts ($m) for CHF, 2012-2022 186
Table 61: Global CHF Market - Drivers and Barriers, 2012-2022 188
Table 62: Sales Forecasts ($m) for CHF in the United States, 2012-2022 193
Table 63: Key Events Impacting Sales for CHF in the United States, 2012-2022 195
Table 64: CHF Market in the United States - Drivers and Barriers, 2012-2022 195
Table 65: Sales Forecasts ($m) for CHF in the France, 2012-2022 198
Table 66: Key Events Impacting Sales for CHF in France, 2012-2022 200
Table 67: CHF Market - Drivers and Barriers in France, 2012-2022 200
Table 68: Sales Forecasts ($m) for CHF in Germany, 2012-2022 202
Table 69: Key Events Impacting Sales for CHF in Germany, 2012-2022 204
Table 70: CHF Market in Germany - Drivers and Barriers, 2012-2022 204
Table 71: Sales Forecasts ($m) for CHF in Italy, 2012-2022 206
Table 72: Key Events Impacting Sales for CHF in Italy, 2012-2022 207
Table 73: CHF Market in Italy - Drivers and Barriers, 2012-2022 208
Table 74: Sales Forecasts ($m) for CHF in Spain, 2012-2022 210
Table 75: Key Events Impacting Sales for CHF in Spain, 2012-2022 211
Table 76: CHF Market in Spain - Drivers and Barriers, 2012-2022 212
Table 77: Sales Forecasts ($m) for CHF in the United Kingdom, 2012-2022 214
Table 78: Key Events Impacting Sales for CHF in the United Kingdom, 2012-2022 216
Table 79: CHF Market - Drivers and Barriers in the United Kingdom, 2012-2022 216
Table 80: Sales Forecasts ($m) for CHF in Japan, 2012-2022 218
Table 81: Key Events Impacting Sales for CHF in Japan, 2012-2022 220
Table 82: CHF Market in Japan - Drivers and Barriers, 2012-2022 220
Table 83: Key Launch or Approval Dates 247
Table 84: Key Patent Expiries 247
Table 85: Physicians Surveyed, By Country 256

1.2 List of Figures
Figure 1: Worsening HF Leading to Chronic Disease 25
Figure 2: All Markets, Prevalent Cases (N) of CHF, Ages ?45 Years, Men and Women, 2012-2022 51
Figure 3: All Markets, Prevalent Cases of CHF, by Age, Men and Women, N, 2012 54
Figure 4: All Markets, Prevalent Cases of CHF, by Sex, Ages ?45 Years, %, 2012 56
Figure 5: All Markets, Prevalent Cases of CHF, by Age and Sex, N, 2012 57
Figure 6: China, Prevalent Cases of CHF by Age and Sex, N, 2012 58
Figure 7: All Markets, Age-Standardized Prevalence of CHF, Ages ?45 Years, Men and Women, %, 2012 60
Figure 8: Drug-Treatment Rates of Patients Diagnosed with CHF in the 7MM, by NYHA Class 68
Figure 9: Treatment of CHF Patients by Drug Class, US, 2012 77
Figure 10: Treatment of CHF Patients by Drug Class, France, 2012 79
Figure 11: Treatment of CHF Patients by Drug Class, Germany, 2012 81
Figure 12: Treatment of CHF Patients by Drug Class, Italy, 2012 83
Figure 13: Treatment of CHF Patients by Drug Class, Spain, 2012 86
Figure 14: Treatment of CHF Patients by Drug Class, UK, 2012 89
Figure 15: Treatment of CHD Patients by Drug Class, Japan, 2012 91
Figure 16: CHF Therapeutics - Clinical Trials by Country, 2012 142
Figure 17: Global Sales for CHF ($bn) by Region, 2012-2022 187
Figure 18: Sales for CHF ($bn) in the United States, 2012-2022 194
Figure 19: Sales for CHF ($m) in France, 2012-2022 199
Figure 20: Sales for CHF in Germany ($m), 2012-2022 203
Figure 21: Sales for CHF ($m) in Italy, 2012-2022 207
Figure 22: Sales for CHF ($m) in Spain, 2012-2022 211
Figure 23: Sales for CHF ($m) in the United Kingdom, 2012-2022 215
Figure 24: Sales for CHF ($m) in Japan, 2012-2022 219


To order this report: PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029811/PharmaPoint-Chronic-Heart-Failure---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow